Fundies.
English

Segment disclosures

Company overview

Burning Rock Biotech Limited

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

3 dimension combinations 36 retained observations 10 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Central Laboratory Business

Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bnr:CentralLaboratoryBusinessMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31159993000 CNY20260428Open filing evidence
2025-01-01 – 2025-12-3122878000 USD20260428Open filing evidence
2024-01-01 – 2024-12-31175649000 CNY20260428Open filing evidence
2024-01-01 – 2024-12-3124064000 USD20250429Open filing evidence
2023-01-01 – 2023-12-31232812000 CNY20260428Open filing evidence
2022-01-01 – 2022-12-31314770000 CNY20250429Open filing evidence
2022-01-01 – 2022-06-30152808000 CNY20221107Open filing evidence
2021-01-01 – 2021-12-31319353000 CNY20240429Open filing evidence
2021-01-01 – 2021-06-30154560000 CNY20221107Open filing evidence
2020-01-01 – 2020-12-31297342000 CNY20230420Open filing evidence
2019-01-01 – 2019-12-31276254000 CNY20220429Open filing evidence
2018-01-01 – 2018-12-31161458000 CNY20210323Open filing evidence

Inhospital Business

Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bnr:InhospitalBusinessMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31224035000 CNY20260428Open filing evidence
2025-01-01 – 2025-12-3132037000 USD20260428Open filing evidence
2024-01-01 – 2024-12-31224492000 CNY20260428Open filing evidence
2024-01-01 – 2024-12-3130755000 USD20250429Open filing evidence
2023-01-01 – 2023-12-31188701000 CNY20260428Open filing evidence
2022-01-01 – 2022-12-31175296000 CNY20250429Open filing evidence
2022-01-01 – 2022-06-3083134000 CNY20221107Open filing evidence
2021-01-01 – 2021-12-31165116000 CNY20240429Open filing evidence
2021-01-01 – 2021-06-3069496000 CNY20221107Open filing evidence
2020-01-01 – 2020-12-31117872000 CNY20230420Open filing evidence
2019-01-01 – 2019-12-3187678000 CNY20220429Open filing evidence
2018-01-01 – 2018-12-3133186000 CNY20210323Open filing evidence

Pharma Research And Development Services

Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bnr:PharmaResearchAndDevelopmentServicesMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31155540000 CNY20260428Open filing evidence
2025-01-01 – 2025-12-3122242000 USD20260428Open filing evidence
2024-01-01 – 2024-12-31115681000 CNY20260428Open filing evidence
2024-01-01 – 2024-12-3115848000 USD20250429Open filing evidence
2023-01-01 – 2023-12-31115922000 CNY20260428Open filing evidence
2022-01-01 – 2022-12-3173172000 CNY20250429Open filing evidence
2022-01-01 – 2022-06-3030428000 CNY20221107Open filing evidence
2021-01-01 – 2021-12-3123393000 CNY20240429Open filing evidence
2021-01-01 – 2021-06-309846000 CNY20221107Open filing evidence
2020-01-01 – 2020-12-3114689000 CNY20230420Open filing evidence
2019-01-01 – 2019-12-3117745000 CNY20220429Open filing evidence
2018-01-01 – 2018-12-3114223000 CNY20210323Open filing evidence